Salbutamol Research Articles

Effect of Salbutamol on the Disposition Kinetics of Levofloxacin in the Plasma and Lung of Rats.

Antibiotics and bronchodilator drugs can be used together in respiratory distress caused by bacterial infections. Levofloxacin (LVX) and Salbutamol (SLB) can be used simultaneously in respiratory distress. However, there have been no investigations on how the concurrent use of SLB can affect the pharmacokinetics of LVX in rats. The purpose of this study was to investigate the influence of SLB on the plasma and lung pharmacokinetics of LVX in rats. A total of 132 rats were randomly assigned to two groups: LVX (n=66) and LVX+SLB (n=66). LVX (intraperitoneal) and SLB (oral) were administered to rats at doses of 50 and 3 mg/kg, respectively. The concentrations of LVX in the plasma and lungs were determined through the utilization of high-performance liquid chromatography along with UV. Pharmacokinetic parameters were assessed by non-compartmental analysis. The area under the curve from 0 to 16 h (AUC0-16), terminal elimination half-life, volume of distribution, total body clearance, and peak concentration of LVX in the plasma were 42.57 h*μg/mL, 2.32 h, 3.91 L/kg, 1.17 L/h/kg, and 23.96 μg/mL, respectively. There were no alterations observed in the plasma and lung pharmacokinetic parameters of LVX when co-administered with SLB. The AUC0-16 lung/AUC0-16 plasma ratios of LVX were 1.60 and 1.39 after administration alone and co-administration with SLB, respectively. The concentration of LVX in lung tissue was higher than that in plasma. SLB administration to rats did not affect the plasma and lung pharmacokinetics and lung penetration ratio of LVX. There is a need to reveal the change in the pharmacokinetics of LVX after multiple administration of both drugs and after administration of SLB by different routes.

Impact of nebulization versus metered-dose inhaler utilization on viral particle dispersion in patients with COVID-19.

Conflicting guidance exists regarding the characterization of nebulization as an aerosol-generating procedure and subsequent risk of transmission of SARS-CoV-2 to healthcare workers. This study sought to address whether SARS-CoV-2 viral load distribution was impacted by bronchodilator delivery via nebulizer versus metered-dose inhaler (MDI). Adults infected with COVID-19 were enrolled and received a single dose of albuterol sulfate nebulized solution (2.5mg/3mL via breath-actuated nebulizer with filtered mouthpiece) or albuterol sulfate hydrofluoroalkane inhalation aerosol (90µg/actuation; two puffs via MDI with spacer) in a randomized crossover sequence. Air and surfaces were sampled at predefined locations within patients' hospital rooms to assess SARS-CoV-2 dispersion over three periods (baseline, MDI, and nebulizer). Eleven patients received crossover therapy. Six patients had detectable SARS-CoV-2 RNA during one treatment period (n = 3 each for MDI and nebulizer) and one during both treatment periods. No viral RNA was found in the rooms of four (36.4%) patients. Overall, few environmental samples (17/397; 4.3%) contained detectable viral RNA, with no meaningful differences in positivity rate across periods; RNA genome copy numbers were low in positive samples. No correlation between dispersion and patient clinical status or environmental parameters was observed. In this first prospective trial evaluating viral load distribution following use of nebulizer versus MDI in hospitalized patients with COVID-19, low environmental contamination was found regardless of administration method. Findings support the use of either device when needed to treat patients with COVID-19.

Rapid analysis of salbutamol residues in animal-derived food based on the fluorescence of MOFs/MIPs paper-based chips

Mimetic recognition materials for rapid and selective analysis of foodborne contamination from complex foodstuff becomes a hot research topic in the field of food safety. In this work, borate-affinity-functionalized MOF/molecularly imprinted polymer paper-based microfluidic chips (FSU-BA@MIP) were prepared by growing functionalized MOFs on paper surface with 3-carboxyphenylboronic acid (3-CPBA) as the ligands, followed by coating of a MIP layer of salbutamol (SAL) through a borate-affinity surface imprinting strategy. Using the obtained paper-based chip as a mimetic recognition and specific enrichment module, the fluorescence sensing platform achieved visual rapid quantitative analysis of SAL with a linear range of 0.1 × 10−2–5.0 mg L−1. The limits of detection and quantification were calculated to be 0.095 and 0.290 μg kg−1, respectively, and the sample loading via lateral flow aid could be completed within 30 min. The obtained MOFs/MIPs paper chips provide an effective way for the rapid analysis of harmful contaminants from different animal-derived foods.

A high-accuracy measurement procedure for salbutamol, ractopamine, and clenbuterol in pork by isotope dilution-liquid chromatography/tandem mass spectrometry

In-depth research into the precise evaluation of enzymatic digestion efficiency and the selection of a suitable deuterium-labelled internal standard remains a gap in the accurate determination of β2-agonists in animal-derived food by isotope dilution-liquid chromatography/tandem mass spectrometry (ID-LC-MS/MS). In this study, the enzymatic digestion conditions were optimized by monitoring the presence of β2-agonist conjugates in positive samples, which proved to be reliable for ensuring complete enzymatic digestion. Comparative analysis of deuterium-labelled internal standards for salbutamol (SAL), ractopamine (RAC), and clenbuterol (CLB) revealed that CLB-D6 and SAL-D9 were less effective in compensating for matrix effects due to hydrogen‑deuterium exchange during MS fragment formation. Consequently, SAL-D3, RAC-D3 and CLB-D9 were chosen for the implementation of ID-LC-MS/MS. The developed method demonstrates high accuracy and precision, with the average recoveries ranging from 93.8% to 107.3% with RSD <6.1%, which can provide higher-order measurement results for β2-agonists in pork.

A Novel Common Canister Protocol for Albuterol Sulfate Metered Dose Inhalers: Conservation Strategy and Clinical Outcomes Amid COVID-19 Pandemic.

The COVID-19 pandemic led to unprecedented shortages of albuterol sulfate metered dose inhalers (MDIs) utilized in the supportive management of respiratory symptoms in patients with SARS-CoV-2 infections. The risk of generating infective aerosols in nebulized treatments increased the demand for metered dose delivery, leading to a worldwide shortage of albuterol sulfate MDIs. Previous common canister protocols involve the recycling and cleaning of canisters for multiple patient use, however have not undergone quality control studies on viral cross-contamination. Torrance Memorial Medical Center utilized an off-label method of common canister administration through spacer devices, forgoing the need for sterilization while conserving albuterol sulfate during a public health emergency. A retrospective review of this emergency department protocol was conducted on 329 patients receiving this novel albuterol sulfate common canister method over a 10-month period between 3/23/2020 to 1/23/2021. Results showed 265 patients (80.5%) had improved aeration determined by breath sounds evaluation by the respiratory therapist and patient interview. Purchasing records reviewed since 3/1/2020 show purchases were sufficient to sustain albuterol sulfate MDI supply so that no treatments were delayed omitted during the 10-month evaluation period. This novel approach to common canister delivery offers a promising measure to conserve a vital inhaled medication during a public health emergency and could serve as a basis for future development of conservation and quality control studies.

The Cost of Medications at a Student-Run Free Clinic in New Haven, Connecticut, 2021-2023.

Haven is a student-run free clinic in New Haven, Connecticut, that serves more than 500 patients annually. Haven's pharmacy department helps patients obtain medications by providing discount coupons or medications from the clinic's in-house pharmacy, directly paying for medications at local pharmacies, and delivering medications to patients' homes. This study aimed to identify prescriptions that have the highest cost among Haven patients. Our sample consisted of all Haven patients who attended the clinic from March 2021 through March 2023. Patients were eligible to be seen at Haven if they were aged 18 to 65 years, lacked health insurance, and lived in New Haven. We determined the lowest cost of each medication prescribed to Haven patients by comparing prices among local pharmacies after applying a GoodRx discount. We defined expensive medication as more than $20 per prescription. We excluded medical supplies. Of the 594 Haven patients in our sample, 64% (n = 378) required financial assistance and 22% (n = 129) were prescribed at least 1 expensive medication. Among 129 patients prescribed an expensive medication, the mean (SD) age was 45.0 (12.3) years; 65% were women, and 87% were Hispanic or Latino. Median (IQR) household annual income was $14,400 [$0-$24,000]. We identified 246 expensive medications; the median (IQR) price per prescription was $31.43 ($24.00-$52.02). The most frequently prescribed expensive medications were fluticasone propionate/salmeterol (accounting for 6% of all expensive medications), medroxyprogesterone acetate (6%), albuterol sulfate (5%), and rosuvastatin (5%). The average Haven patient has an income well below the federal poverty level, and many have chronic cardiovascular and respiratory conditions that require expensive medications. Future research should work toward making medications universally affordable.

The pharmacist will see you now: Pharmacist prescriptive authority and access to care

AbstractIn 2018, Idaho became the first state to grant broad prescriptive authority to pharmacists for select medications, such as rescue inhalers (a drug to prevent and treat asthmatic symptoms) and insulin pen needles (for people with diabetes). We analyze the impact of this reform on Medicare beneficiaries' access to these time‐sensitive treatments. Our findings reveal increased Medicare Part D claims, 30‐day fills, and 30‐day supplies of albuterol sulfate and insulin pen needles following expanded pharmacist authority. This translates to approximately three additional patients per pharmacist receiving timely care, potentially preventing costly alternatives such as emergency room visits.

Asma eksaserbasi akut dengan hipertensi urgensi dan obesitas: sebuah laporan kasus

Introduction: Asthma is a chronic inflammatory disease characterized by the rapid and reversible narrowing of the airways. Various factors can influence exacerbations in asthma, and one of the comorbidities is obesity. Inflammation and compensatory mechanisms are related to the occurrence of urgent hypertension in patients with acute exacerbation of asthma, making the analysis and management of asthma exacerbation with comorbidities of obesity and urgent hypertension require special attention and consideration. Case Presentation: This study reports a 17-year-old adolescent with a history of asthma experiencing an acute exacerbation. Comorbidities include obesity with a BMI of 34.6 kg/m2 and urgent hypertension with a blood pressure of 200/100 mmHg. Physical examination revealed wheezing in both lung fields and epigastric tenderness. Radiological examination, including chest X-ray, was within normal limits, while hematological examination showed neutrophilia (8.65 x 103/uL) and 81.4% neutrophil percentage. The patient experienced hypoglycemia (blood glucose of 75 mg/dL). Nebulized bronchodilator therapy with ipratropium bromide, albuterol sulfate, and budesonide corticosteroids was initiated, but respiratory distress persisted. Initial management included oxygenation, intravenous saline, and ranitidine injection, followed by intravenous maintenance fluid with D5 ½ NS, nebulized bronchodilators and corticosteroids, intravenous dexamethasone, intravenous ranitidine, and oral therapy with azithromycin, cetirizine, N-acetylcysteine, and bisoprolol. The patient underwent intensive care for two days with a total treatment duration of six days. Conclusion: Asthma exacerbation with comorbidities of obesity and urgent hypertension requires holistic analysis and management to prevent complications and worsening exacerbations.

A novel approach to detect salbutamol as a doping agent in athletes: A nanoparticle-modified electrode

This study successfully demonstrated a novel approach for the detection of salbutamol (SBM), a common doping drug in sports, using Tb4O7 nanoparticles and a reduced graphene oxide (Tb4O7/RGO) nanocomposite. The electrode modified with the Tb4O7/RGO nanocomposite exhibited remarkable selectivity, stability, and reproducibility, indicating its potential as a useful instrument for real-world uses. When used to detect salbutamol in serum samples, the sensor demonstrated a recovery rate of more than 96.50% and a relative standard deviation (RSD) of less than 4.17% (n=5). This work provides new insights into the electrochemical behavior of salbutamol and creates avenues for the development of very effective doping detection techniques. The sensor set a detection limit of 21 nM and functioned within a linear range of 1 µM to 710 µM. These results illustrate the accuracy and precision of the sensor and highlight its strong performance and dependability in a clinical context. As a result, the proposed sensor could be successfully used to determine the clinical levels of salbutamol in serum samples, giving medical personnel an invaluable tool for tracking and controlling patient health. With potential uses beyond sports doping detection, this work constitutes a noteworthy advancement in the field of electrochemical sensors.

Development of CuO nanoparticles modified electrochemical sensor for detection of salbutamol

Abstract Metal oxide structures are being utilized in an increasing variety of applications. This study used cyclic and differential pulse voltammetry techniques to investigate the possible utilization of copper oxide (CuO) nanoparticles modified carbon paste electrode (CPE) for the redox reactions of salbutamol (SAL). The electrochemical performance of the SAL analyte in a complex matrix environment in Ventolin was evaluated in order to assess the appropriateness of the proposed sensor in a real sample environment. CuO nanoparticles were produced via a straightforward, cost-effective and efficient sol–gel method, and characterization studies of synthesized CuO nanoparticles were performed by scanning electron microscopy, x-ray Diffraction (XRD), and x-ray photoelectron spectroscopy. The synthesized CuO nanoparticles had a spherical shape and particle size was found to be 74 nm. The crystal size of the CuO particles was calculated to be 21.79 nm using the Debye–Scherrer equation. Under optimal conditions, differential pulse voltammetry demonstrated a linear response in the 50 nM to 100 μM range, with a salbutamol detection limit of 50 nM (S/N = 3). The SAL concentration (R 2 = 0.9971) was found to have a good correlation coefficient. The reproducibility of the biosensor was investigated and evaluated with a relative standard deviation of 3% (n = 8). The storage stability of CuO modified CPE for two weeks was evaluated based on the response of DP current measured at intervals every two days. According to the measurement results, the modified electrode exhibited good stability and reproducibility while maintaining 80% of its stability. It is also a rapid and dependable sensor candidate with a measurement time of approximately 20 s. The developed electrode has been utilized successfully to determine doping material with improved performance.

Assessment of bronchodilator responsiveness to salbutamol or ipratropium using different criteria in treatment-naïve patients with asthma and COPD

ABSTRACT Background The criteria for significant bronchodilator responsiveness (BDR) were published in 2005 by the European Respiratory Society/American Thoracic Society, which were revised in 2021, however, data on the agreement between these two recommendations in untreated patients with airflow limitation are missing. Aims We aimed to study BDR to salbutamol (SABA) or ipratropium bromide (SAMA) in patients with suspected bronchial asthma or COPD at initial clinical presentation using the 2005 and 2021 criteria and explore clinical factors associated with BDR+. Methods Symptomatic, treatment-naïve patients with expiratory airflow limitation (n = 105, 57 men, age (mean ± standard deviation): 65 ± 10 years) underwent BDR testing with 400 mcg salbutamol (day 1) or 80 mcg ipratropium bromide (day 2) and BDR was measured after 15 and 30 minutes. Clinical factors with risk for BDR+ were assessed with binomial logistic regression analysis. Results We found a good agreement between the number of 2005-BDR+ and 2021-BDR+ patients at 15 and 30 minutes post-salbutamol and post-ipratropium (88.6–94.8%). More patients showed BDR+ after 30 minutes than following 15 minutes using either criterion. When results at 30 minutes are considered, the number of patients with 2005-BDR+ (82%) was higher than that of 2021-BDR+ (75%), with the proportion of SAMA+ patients being higher than that of SABA+ (2005: 70% vs. 49%, Fisher exact p < 0.01; 2021: 64% vs. 41%, p = 0.001). 2005-BDR+ and 2021-BDR+ to SABA were associated with decreasing pre-BD FEV1% predicted and the presence of cough. More patients with asthma were in the SABA+ group compared to the SAMA+ group (2005: 71% vs. 53%, Fischer exact p = 0.04; 2021: 77% vs. 52%, p = 0.02). Conclusions Fewer patients show BDR+ according to the 2021 criteria in comparison with the 2005 recommendations, and protocols for BDR testing may consider the assessment of response to both SABA and SAMA after 30 minutes.

Aerosol Delivery to Simulated Spontaneously Breathing Tracheostomized Adult Model With and Without Humidification.

Optimal aerosol delivery methods for spontaneously breathing patients with a tracheostomy remain unclear. Thus, we aimed to assess the impact of nebulizer placement, flow settings, and interfaces on aerosol delivery by using a vibrating mesh nebulizer and a jet nebulizer in line with unheated humidification. An 8.0-mm tracheostomy tube was connected to the lung model that simulates adult breathing parameters via a collecting filter. Albuterol sulfate (2.5 mg/3 mL) was administered via a vibrating mesh nebulizer and a jet nebulizer, which was placed in line with unheated humidification provided by a large-volume nebulizer, with FIO2 set at 0.28, with gas flows of 2 L/min versus 6 L/min. Nebulizers were placed in line distal and proximal to the lung model by using a tracheostomy collar and a T-piece. Conventional nebulization was tested using a vibrating mesh nebulizer and a jet nebulizer directly connected to the tracheostomy tube bypassing the humidification device. The drug was eluted from the collecting filter and assayed with ultraviolet spectrophotometry (276 nm). During in-line nebulizer placement with unheated humidification, the inhaled dose was 2-4 times higher with a gas flow of 2 L/min than 6 L/min, regardless of nebulizer type, placement, or interface (all P < .05). At 6 L/min, the inhaled dose was higher with proximal than distal placement when using both interfaces, but, at 2 L/min, the inhaled dose was lower with proximal placement. With a jet nebulizer, the tracheostomy collar generated a higher inhaled dose at proximal placement compared with the T-piece, whereas the T-piece resulted in a higher inhaled dose than the tracheostomy collar with distal placement, regardless of the flow settings. Compared with conventional nebulization using a vibrating mesh nebulizer, an in-line vibrating mesh nebulizer with a large-volume nebulizer at 2 L/min had a similar inhaled dose, regardless of nebulizer placement and interface. In contrast, the in-line jet nebulizer was influenced by both placement and interface. Aerosol delivery with an in-line vibrating mesh nebulizer and jet nebulizer with unheated humidification was affected by nebulizer placement, interface, and gas flow settings.

Layer-by-Layer Biopolymer Assembly for the In Situ Fabrication of AuNP Plasmonic Paper-A SERS Substrate for Food Adulteration Detection.

Here, we introduce an environmentally friendly approach to fabricate a simple and cost-effective plasmonic paper for detecting food additives using surface-enhanced Raman spectroscopy (SERS). The plasmonic paper is fabricated by in situ growth of gold nanoparticles (AuNPs) on filter paper (FP). To facilitate this green fabrication process, we applied a double-layered coating of biopolymers, chitosan (CS) and alginate (ALG), onto the FP using a layer-by-layer (LbL) assembly through electrostatic interactions. Compared to single-layer biopolymer coatings, double-layered biopolymer-coated paper, ALG/CS/FP, significantly improves the reduction properties. Consequently, effective in situ growth of AuNPs can be achieved as seen in high density of AuNP formation on the substrate. The resulting plasmonic paper provides high SERS performance with an enhancement factor (EF) of 5.7 × 1010 and a low limit of detection (LOD) as low as 1.37 × 10-12 M 4-mercaptobenzoic acid (4-MBA). Furthermore, it exhibits spot-to-spot reproducibility with a relative standard deviation (RSD) of 8.2% for SERS analysis and long-term stability over 50 days. This paper-based SERS substrate is applied for melamine (MEL) detection with a low detection limit of 0.2 ppb, which is sufficient for monitoring MEL contamination in milk based on food regulations. Additionally, we demonstrate a simultaneous detection of β-agonists, including ractopamine (RAC) and salbutamol (SAL), exhibiting the multiplexing capability and versatility of the plasmonic paper in food contaminant analysis. The development of this simple plasmonic paper through the LbL biopolymer assembly not only paves the way for novel SERS substrate fabrication but also broadens the application of SERS technology in food contaminant monitoring.

Formulation and Evaluation of Pulsatile drug delivery of Albuterol sulphate and Theophylline drugs using modified Pulsincap technology

Albuterol Sulphate and Theophylline are used as anti-asthma agents. The objective of the present investigation was to design develop and evaluate a modified pulsincap drug delivery system of Albuterol Sulphate and Theophylline for the treatment of Asthma. The body of capsule was made insoluble with water by cross linking with formaldehyde. This modified capsule was completely filled with drug with polymer such as HPMCK15M, HPMC K 100M, PVPK-30 to expel the drug after predetermined lag time. A hydrogel plug was inserted in the body of a capsule to obtain desired drug release after a lag time for chronotherapy of asthma. Untreated capsule was attached to the treated body and was released. The drug was exerted to precompression parameter such as Angle of repose, Bulk density, Tapped density, Car’s index Hassner’s ratio. These capsules were subjected to further post formulation studies such as weight variation, drug content, invitro dissolution studies separately. The pre and post formulation parameters were found to be within permissible limit. The mere compatibility of drug, polymer and excipients were determined by Fourier transform infrared analysis (FTIR) and UV-Visible spectroscopy (UV). The results showed that drug was completely compatible with polymer and excipients. In vitro dissolution were carried out by using pH 6 .8 and pH 7.4 buffers. Based on the result obtained F5 Formulation shows good dissolution profile. Higuchi, Hixson crowell. Koresmeyer peppas to evaluate the kinetics and drug release. The drug release follows first order kinetics and the mechanism was found to be NON FICKS DIFFUSION.&#x0D; Keywords: Albuterol Sulphate, Theophylline, modified pulsincap drug delivery system, FTIR, Dissolution

Design, Evaluation and Optimization of Albuterol Sulphate and Theophylline Pulsincap drug delivery system for chronotherapy of Asthma

The aim of the current study was to design and develop and evaluate pulsatile drug delivery system of Albuterol Sulphate and Theophylline for the treatment of Asthma. The capsule body was made water insoluble by cross linked with formaldehyde vaopur. The treatment of Formalin was adopted to modify the gelatin capsule solubility. The formalin residue was carried out by quantitative test. The drug-excipient compatibility is done by FTIR and UV . The pulsincap formulation were prepared by using hydrogel plug of various components. The drug content of the formulation of pulsincap was found to be in the general range. The invitro drug release studies in ph1.2 .6.2 and 7.4 buffern was noticed to be zero percent and capsule was stable for 2 hours drug the studyF5 formulation batch was selected which was best and good formulation and promoted maximum drug release of 96.29% percentage at phosphate buffers when compared with other formulation. Pulsincap formulation can be adopted for optimum delivery of pellets in the treatment as per chronotherapy&#x0D; Keywords: Theophylline, quantitative test, invitro drug release studies, phosphate buffers6.2 and 7.4.

Budesonide/Formoterol or Budesonide/Albuterol as Anti-Inflammatory Reliever Therapy for Asthma

Over use of reliever as short acting beta-agonist (SABA) and associated underuse of controller as inhaled corticosteroid (ICS) administered via separate inhalers results in worse asthma outcomes . Such discordance can be obviated by combining both controller and reliever in the same inhaler. So called anti-inflammatory reliever (AIR) therapy comprises the use of a single inhaler containing an ICS such as budesonide (BUD) in conjunction with a reliever as either albuterol (ALB) or formoterol (FORM) ,to be used on demand with variable dosing driven by asthma symptoms in a flexible patient centred regimen. Global guidelines now support the use of BUD-ALB as AIR therapy to reduce exacerbations , either on its own in mild asthma or in conjunction with fixed dose maintenance ICS-long acting beta-agonist (LABA) in moderate to severe asthma . Using BUD-FORM on its own allows patients to seamlessly move in an intuitive flexible fashion between AIR or maintenance and reliever therapy (MART) , by stepping up and down the dosing escalator across a spectrum of asthma severities . Head to head clinical studies are indicated to compare BUD-FORM versus BUD-ALB as AIR in mild asthma ,and also BUD-FORM as MART versus BUD-ALB as AIR plus maintenance ICS-LABA in moderate to severe asthma. Patients should be encouraged to make an informed decision in conjunction with their health care professional regarding the best therapeutic option tailored to their individual needs , which in turn is likely to result in long term compliance and associated optimal asthma control.

Electrochemical determination of salbutamol in aqueous solutions with UiO‐66/rGO‐modified electrodes

AbstractThe synthesis of the UiO‐66/rGO material involved combining UiO‐66 with reduced graphene oxide (rGO). This resulting composite found application in the electrochemical determination of salbutamol (SAL) through modification of a glassy‐carbon electrode (GCE) with UiO‐66/rGO. Differential pulse voltammetry served as the chosen technique, offering a wide linear range spanning 1–160 µm and demonstrating a low limit of detection at 0.84 µm. To ensure the reliability of the electrode, various aspects such as sensitivity, repeatability, reproducibility, and stability were meticulously studied. When applied to the analysis of SAL in swine urine solutions (n = 3), the electrode exhibited good recovery rates. Remarkably, the results obtained through this method correlated well with those acquired using ultra‐high performance liquid chromatography (UPLC).

Chromatographic analysis of triple cough therapy; bromhexine, guaiafenesin and salbutamol and pharmaceutical impurity: in-silico toxicity profile of drug impurity

Bromhexine (BR), guaiafenesin (GUF) and salbutamol (SAL) are formulated as Ventocough syrup® (with and without sugar), labeled to contain propyl paraben and sodium benzoate as inactive ingredients. They are used to make coughing more productive and easier. A crucial element and a major issue in the pharmaceutical industry is the control of organic related impurities to obtain safe and effective treatment. Guaiacol (GUL) is reported to be GUF related impurity that was proved to be extremely toxic (toxic rating class 5), and its use should be banned. In this work, In-Silico study and ADMET estimation were conducted to predict GUL pharmacokinetic properties and its toxicity profile. Additionally, two chromatographic methods were conducted to analyze the studied components along with GUF impurity in the presence of the labeled dosage form excipients. The In-Silico study assured that GUL has oral rat acute toxicity and it is considered to be skin sensitizer. On the other hand, the developed TLC- densitometeric method depended on using a mobile phase mixture of hexane: methylene chloride: triethylamine (5.0:6.0:0.3, by volume) as a developing system. UV-Scanning was performed immediately at 275 nm for SAL, GUF and GUL, while scanning at 310 nm was used for scanning BR. Linearity was established in the ranges of 0.25–4.0, 0.25–4.0, 0.5–8.0 and 0.1–1.6 µg/band for BR, SAL, GUF and GUL, respectively. In the developed HPLC method, separation was performed on X-Bridge® C18 column (250 × 4.6 mm, 5 μm) using a solvent mixture of 0.05M disodium hydrogen phosphate pH 3 with aqueous phosphoric acid: methanol (containing 0.3%, v/v triethylamine) (40:60, v/v). Detection was done at 225 nm and separation was achieved within 10 min. Linearity was proved in the range of 2–50 µg/mL for the proposed drugs. Validation of the developed methods was done and all the calculated parameters were within the acceptable limits recommended by ICH guidelines. After that, methods were used to examine the potency of the selected marketed dosage forms and concentrations of all drugs were within the acceptable limits. Additionally, complete separation between the studied drugs and the additives were observed. The developed methods can be used during routine quality control analysis of the proposed drugs when the required issues concern on sensitivity, selectivity and analysis time.Graphical

Oxidized low-density lipoprotein induces M2-type differentiation of macrophages to promote the protracted progression of atherosclerotic inflammation in high-fat diet-fed ApoE -/- mice.

In this study, the significance of oxidized low-density lipoprotein (ox-LDL) in promoting the progression of atherosclerosis was investigated by inducing the differentiation of macrophages into the M2 subtype within a high-fat diet-induced ApoE -/- mouse model. The study also evaluated the effects of β2-AR agonists and blockers on this process. Ox-LDL was found to have significantly promoted the differentiation of macrophages into the M2 type and induced related functional alterations. Furthermore, it activated the pyroptosis pathway and encouraged the release of lactate dehydrogenase. The administration of β2-AR agonists intensified these processes, while β2-AR blockers had the opposite effect. In animal experiments, the model group displayed elevated numbers of M2-type macrophages beneath the aortic root intima, an increased rate of plaque destruction, and the formation of atherosclerotic plaques compared to the control group. The SAL (Salbutamol) group exhibited even more severe plaque development than the model group. Conversely, the ICI (ICI118551) group demonstrated M2-type macrophage levels comparable to the control group, with a higher plaque destruction rate than controls but significantly lower than the model group, and no atherosclerotic plaques. These findings suggest that ox-LDL promoted the differentiation of recruited monocytes into M2-type macrophages, leading to a shift in the inflammatory response from M1 to M2 macrophages. This alteration resulted in the persistence of atherosclerotic inflammation, as M2-type macrophages were prone to cell membrane rupture (such as pyroptosis), contributing to the continuous recruitment of circulating monocytes and heightened inflammatory reactions within atherosclerotic plaques. Consequently, this process fueled the progression of atherosclerosis.

Single-walled carbon nanotube coated with Ponceau4R-doped over-oxidized polypyrrole as a sensitive sensor for voltammetric monitoring of salbutamol

A sensitive voltammetric sensor is fabricated by the electrochemical oxidation of polypyrrole (PPy) on a glassy carbon electrode surface covered with a thin film of single-walled carbon nanotubes (SWCNT/GCE). Ponceau4R (P4R) used as an anionic dopant controlled the structure, stability, conductivity, and electrochemical properties of the PPy. The porosity and oxygen-containing active sites on the P4R-PPy/SWCNT/GCE were increased by over-oxidation of the PPy layer to achieve P4R-oPPY/SWCNT/GCE. Morphology features of the P4R-oPPY/SWCNT layer are thoroughly characterized using microscopy instruments. The salbutamol (SAL) voltammetric behavior is evaluated by P4R-oPPY/SWCNT/GCE and a mechanism for its electrochemical oxidation is proposed. Optimizing the important parameters in the electrode modification procedure, including the amount of SWCNT and electrochemically deposited P4R-oPPY, and SAL sensing steps such as the solution pH, potential and accumulation time of SAL are optimized precisely. At the best condition, a ~ 20 times enhancement of the SAL oxidation current was observed by P4R-oPPY/SWCNT modifier. Using P4R-oPPY/SWCNT/GCE, a wide two-part linear range of 0.02–10 μM with a detection limit of 6 nM is resulted in the electrochemical measurement of SAL. The P4R-oPPY/SWCNT/GCE with good reproducibility and stability succeeded in correctly measuring SAL in pharmaceutical and clinical samples.